公司本次回购注销部分限制性股票将涉及注册资本减少，根据《中华人民 共和国公司法》和《公司章程》等相关法律、法规的规定，公司特此通知债权 人，债权人自本公告之日起 45 日内，有权要求公司清偿债务或者提供相应的 担保。债权人如果提出要求公司清偿债务的，应根据《中华人民共和国公司 法》等相关法律法规的规定，向公司提出书面请求，并随附相关证明文件。债 权人未在规定期限内行使上述权利的，本次回购注销减少注册资本的相关事宜 将按法定程序继续实施。 证券代码：002690 证券简称：美亚光电 公告编号：2024-025 合肥美亚光电技术股份有限公司 关于回购注销部分已授予限制性股票减资 暨通知债权人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 合肥美亚光电技术股份有限公司（以下简称"公司"）第五届董事会第九 次会议、第五届监事会第八次会议以及2024年第一次临时股东大会，分别审议 通过了《关于回购注销部分限制性股票的议案》。 鉴于首次及预留授予的激励对象中共有3名激励对象已离职，其中，首次授 予部分激励对象离职人数1名，预留授予部分激励对象离职人数3名（本次首次 授 ...

2024 年第一次临时股东大会法律意见书 本所根据《证券法》的要求，按照律师行业公认的业务标准、道德规范和勤 勉尽责精神对本次股东大会相关事项进行了见证，现对本次股东大会的召集、召 开及其他相关事项发表如下意见： 天律意 2024 第 02211 号 法律意见书 一、关于本次股东大会的召集、召开程序 致：合肥美亚光电技术股份有限公司 安徽天禾律师事务所 关于合肥美亚光电技术股份有限公司 根据《中华人民共和国公司法》(下称"《公司法》")、《中华人民共和国 证券法》（下称"《证券法》"）、《上市公司股东大会规则》和《合肥美亚光 电技术股份有限公司章程》（下称"《公司章程》"）的有关规定，安徽天禾律 师事务所接受合肥美亚光电技术股份有限公司（下称"公司"）的委托，指派本 所李军、吕光律师出席公司 2024 年第一次临时股东大会（下称"本次股东大会"）， 并对本次股东大会相关事项进行见证，出具法律意见。 本所同意将本法律意见书作为本次股东大会的公告文件，随公司其他文件一 并报送有关主管部门审查并予以公告。 （二）经查验，本次股东大会现场会议于 2024 年 9 月 10 日下午 14:30 在合 肥市高新技术产业开 ...

合肥美亚光电技术股份有限公司 章程 二〇二四年九月 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东大会 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第五章 董事会 第一节 董事 第二节 董事会 第六章 总经理及其他高级管理人员 第七章 监事会 第一节 监事 第二节 监事会 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第九章 通知与公告 第一节 通知 第二节 公告 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十一章 修改章程 第十二章 附则 第一章 总则 第一条 为维护合肥美亚光电技术股份有限公司（以下简称"公司"）、股东 和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）和 其他有关规定，制订本章程。 第二条 ...

证券代码：002690 证券简称：美亚光电 公告编号：2024-024 合肥美亚光电技术股份有限公司 2024年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 合肥美亚光电技术股份有限公司（以下简称"公司"）董事会于2024年8月 22日在《证券时报》、巨潮资讯网（http://www.cninfo.com.cn）上刊登了《关 于召开2024年第一次临时股东大会的通知》。 （2）现场会议召开地点：合肥市高新技术产业开发区望江西路668号公司会 议室 （3）股权登记日：2024年9月3日 （4）会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式召 开。 1 （5）会议召集人：公司董事会 1、会议召开情况 （1）会议召开时间 现场会议时间：2024 年 9 月 10 日下午 14:30 网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 9 月 10 日上 午 9:15 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of 5% to 15% relative to the benchmark index [2][8] Core Views - The company's short-term performance is under pressure, with H1 2024 revenue declining 3.83% YoY to RMB 930 million and net profit attributable to shareholders dropping 21.48% YoY to RMB 272 million [2] - Q2 2024 showed marginal improvement with revenue growing 6.87% YoY to RMB 599 million, though net profit still declined 22.71% YoY [2] - The company continues to iterate new products and technologies, particularly in color sorters and high-end medical imaging equipment, which could open up new growth opportunities [2] Financial Performance Revenue and Profit - H1 2024 revenue breakdown: color sorter business grew 14.40% YoY to RMB 645 million, while medical equipment, X-ray industrial inspection machines, and parts businesses declined 32.27%, 21.77%, and 13.92% respectively [2] - Gross margin and net margin declined to 50.88% and 29.23% respectively in H1 2024, down 1.62 and 6.57 percentage points YoY [2] Expenses - H1 2024 expense ratios: sales expenses increased 3.03 percentage points to 12.08%, management expenses rose 0.52 percentage points to 5.02%, and R&D expenses grew 1.28 percentage points to 6.31% [2] Future Projections - Revenue is projected to grow from RMB 2.51 billion in 2024E to RMB 3.18 billion in 2026E, with net profit attributable to shareholders expected to increase from RMB 682 million to RMB 864 million over the same period [2][3] - EPS is forecasted to grow from RMB 0.77 in 2024E to RMB 0.98 in 2026E, with P/E ratios declining from 16.41x to 12.96x [2][3] Product Development - The company launched several new products and technologies in H1 2024, including the UHD2.0 high-definition deep learning system and PD-MAR "truth-preserving" imaging technology [2] - These innovations address long-standing industry challenges and could significantly enhance the company's competitive position in both color sorting and medical imaging markets [2] Market Position - The company is a leading provider of photoelectric identification products in China, with its product development and commercialization efforts showing promising results [2] - Contract liabilities increased 93.87% compared to the end of the previous year, indicating strong pre-sales growth [2]

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [1][4]. Core Views - The company's Q2 revenue growth has turned positive year-on-year, although the overall performance has been impacted by foreign exchange losses. The Q2 revenue reached 599 million yuan, representing a year-on-year increase of 6.87%, while the net profit attributable to shareholders was 171 million yuan, down 22.71% year-on-year [1]. - The report highlights the company's focus on expanding its market presence and R&D investment in the dental medical sector, which is expected to benefit from the aging population and a potential recovery in demand [1][2]. - The color selection machine business is performing well, contributing significantly to the company's revenue, while the medical equipment segment is gradually recovering despite facing challenges [2][4]. Summary by Sections Financial Performance - In H1 2024, the company achieved a total revenue of 930 million yuan, a decrease of 3.83% year-on-year, and a net profit of 272 million yuan, down 21.48% year-on-year. The gross margin was 50.88%, a decline of 1.62 percentage points year-on-year [1][4]. - The company’s revenue from the color selection machine, medical equipment, and industrial testing segments were 645 million, 205 million, and 64 million yuan respectively, with year-on-year changes of +14.40%, -32.27%, and -21.77% [1][2]. Market Outlook - The report anticipates that the company will see revenue growth from 2.49 billion yuan in 2024 to 3.28 billion yuan in 2026, with corresponding net profits expected to rise from 710 million yuan to 917 million yuan during the same period [4][5]. - The company is expected to maintain a cautious optimism regarding the medical equipment sector, with new product registrations such as spinal surgery navigation devices and mobile CT expected to drive future growth [2][4]. Valuation Metrics - The report provides a forecast for the company's P/E ratio, which is projected to decrease from 16.28 in 2024 to 12.60 in 2026, indicating an improving valuation as earnings are expected to grow [4][5].

Group 1: Financial Performance - In the first half of 2024, the company achieved a revenue of 930 million yuan, a year-on-year decline of 3.8%, with a nearly 7% growth in the second quarter [2] - The net profit for the first half of 2024 was 272 million yuan, down 21.5% year-on-year, primarily due to reduced exchange gains and increased expenses [2] - The color sorting machine and export businesses experienced approximately 15% growth in the second quarter [2] Group 2: Business Strategy and Market Position - The company is focusing on its core business and actively investing in market opportunities despite a challenging economic environment [2] - Increased investments in sales and R&D expenses were noted, which are expected to support future market competitiveness [2][3] - The company has obtained product registrations in about 50 countries and regions, with small-scale exports of medical products starting in 2024 [3] Group 3: Product Development and Market Trends - The mobile head CT device is suitable for various applications and has significant market potential, currently in the early stages of market application [4] - The company is optimistic about the future of the dental industry, despite current challenges in the dental service sector [2][3] - The company plans to continue promoting new medical products, including spinal surgery navigation devices and mobile head CTs, to achieve market sales [3] Group 4: Financial Management and Future Outlook - The company reduced its cash reserves by 200 million yuan due to cash dividends paid in the first half of 2024 [4] - There are no major capital expenditure plans for 2024, and the company intends to maintain its profit distribution policy [4] - The company aims to deepen its focus on advantageous industries and expand its business scale to achieve better operational results in an uncertain environment [5]

机械设备 证 券 研 究 报 告 2024 年 08 月 23 日 美亚光电 (002690) ——Q2 收入同比转正，医疗新品未来可期 | --- | --- | |------------------------------------|-------------------------------| | 市场数据： | 2024 年 08 月 22 日 | | 收盘价（元） | 13.60 | | 一年内最高 / 最低（元） | 23.80/13.45 | | 市净率 | 5.1 | | 息率（分红/股价） | 5.15 | | 流通 A 股市值（百万元） | 5,881 | | 上证指数/深证成指 | 2,848.77/8,162.18 | | 注："息率"以最近一年已公布分红计算 | | | --- | --- | |-------------------------------|------------------------| | | | | | | | 基础数据 : 2024 | 年 06 月 30 日 | | 每股净资产（元） | 2.68 | | 资产负债率 % | 20.19 | | 总 ...

Investment Rating - The report maintains an "Overweight" rating for the company [1][5] Core Views - The company's revenue for the first half of 2024 was RMB 930 million, a year-on-year decrease of 3.83% [1] - Net profit attributable to the parent company was RMB 272 million, a year-on-year decrease of 21.48% [1] - The color sorter segment remained stable, contributing 69.30% of total revenue, while the medical equipment segment faced pressure, with revenue declining by 32.27% [1][3] Business Segment Analysis Color Sorter Segment - Revenue from the color sorter segment reached RMB 645 million, a year-on-year increase of 14.40% [3] - Gross margin for this segment was 49.03%, a slight decrease of 1.41 percentage points compared to the previous year [3] - The company launched several innovative products, including the UHD2.0 high-definition deep learning system and the new KR color sorter with intelligent panoramic imaging technology [3] Medical Equipment Segment - Revenue from the medical equipment segment was RMB 205 million, a year-on-year decrease of 32.27% [3] - Gross margin for this segment was 51.04%, a decrease of 4.23 percentage points compared to the previous year [3] - The company is actively expanding into non-dental medical imaging fields, with products such as spinal surgical navigation equipment and mobile head CTs [3] Industrial Inspection Segment - Revenue from the industrial inspection segment was RMB 63.66 million, a year-on-year decrease of 21.77% [4] - The company continues to optimize its product line, focusing on engineering design and intelligent production to enhance product reliability [4] Financial Forecast - The report revised down the company's net profit forecast for 2024-2026 to RMB 744 million, RMB 849 million, and RMB 937 million, respectively [5] - EPS for 2024-2026 is expected to be RMB 0.84, RMB 0.96, and RMB 1.06, respectively [5] - The current stock price corresponds to a PE ratio of 16x, 14x, and 13x for 2024-2026 [5] Key Financial Data - Revenue growth for 2024-2026 is projected at 2.75%, 13.72%, and 10.32%, respectively [6] - Net profit growth for 2024-2026 is expected to be -0.16%, 14.20%, and 10.28%, respectively [6] - The company's ROE is forecasted to increase from 27.00% in 2023 to 38.79% in 2026 [9]

Investment Rating - The investment rating for the company is "Buy" [3] Core Views - The company's performance in H1 2024 showed a revenue of 930 million yuan, a year-over-year decrease of 3.8%, and a net profit attributable to shareholders of 270 million yuan, down 21.5% year-over-year. However, Q2 2024 saw a revenue increase to 600 million yuan, up 6.9% year-over-year, indicating a positive trend [2][3] - The company is experiencing a recovery in its operational status since Q2 2024, with revenue growth driven by its color sorting machine and export businesses, while the medical-related business is gradually recovering despite facing challenges [2][3] - The color sorting machine segment generated 640 million yuan in revenue in H1 2024, reflecting a year-over-year growth of 14.4%. The company has launched several innovative products, enhancing its competitive edge in both domestic and international markets [2][3] - The medical equipment segment, particularly the CBCT, reported a revenue of 210 million yuan in H1 2024, down 32.3% year-over-year. However, new product launches and market recovery are expected to drive growth in this segment [2][3] Summary by Sections Performance Analysis - H1 2024 revenue was 930 million yuan, with a net profit of 270 million yuan, showing a decline compared to the previous year. Q2 2024 revenue was 600 million yuan, indicating a positive trend [2] - The company’s gross margin for H1 2024 was 50.9%, a decrease of 1.6 percentage points year-over-year, while the net profit margin was 29.2%, down 6.6 percentage points year-over-year [2] Growth Potential - The color sorting machine business is expected to continue its stable growth, supported by new technologies and products. The medical equipment segment is anticipated to recover as market conditions improve [2][3] Profitability Forecast - EPS for 2024-2026 is projected to be 0.83, 0.95, and 1.09 yuan respectively, with a current PE ratio of 17.1 times for 2024. The company is expected to maintain stable growth in its core businesses [2][3]